PMID- 38526239
OWN - NLM
STAT- MEDLINE
DCOM- 20240326
LR  - 20240326
IS  - 1607-8454 (Electronic)
IS  - 1024-5332 (Linking)
VI  - 29
IP  - 1
DP  - 2024 Dec
TI  - Outcomes and adverse events in older acute lymphoblastic Leukemia patients 
      treated with a pediatric-inspired protocol with Pegylated or native Asparaginase.
PG  - 2329027
LID - 10.1080/16078454.2024.2329027 [doi]
AB  - This retrospective report presents the outcomes and adverse events (AEs) observed 
      in 73 patients aged 60 years or older diagnosed with Philadelphia 
      Chromosome-negative Acute Lymphoblastic Leukemia (Ph-negative ALL) treated with a 
      pediatric-inspired protocol incorporating either Pegylated (PEG-ASP) or Native 
      Asparaginase (EC-ASP). Notably, 61% of patients experienced AEs of Grade III-IV 
      severity. The most prevalent AEs included thrombosis (35.6%), febrile neutropenia 
      (38.4%), and transaminitis (34.2%). AEs did not translate into significant 
      differences concerning overall survival, leukemia-free survival, or early 
      mortality. Furthermore, we observed a reduction in early mortality rates (11% vs. 
      20%) and an increase in median overall survival (54 vs. 48 months) compared to 
      our previous data. These findings suggest that the utilization of a 
      pediatric-inspired chemotherapy protocol, with ASP, is an effective and 
      well-tolerated therapeutic option for older patients with Ph-negative ALL. 
      However, it emphasizes the importance of diligent monitoring and close follow-up 
      throughout treatment.
FAU - Perusini, Maria Agustina
AU  - Perusini MA
AUID- ORCID: 0000-0003-1893-6096
AD  - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 
      Toronto, Canada.
FAU - Andrews, Claire
AU  - Andrews C
AD  - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 
      Toronto, Canada.
FAU - Atenafu, Eshetu G
AU  - Atenafu EG
AUID- ORCID: 0000-0002-4613-3680
AD  - Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Canada.
FAU - Gupta, Vikas
AU  - Gupta V
AUID- ORCID: 0000-0002-1419-8607
AD  - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 
      Toronto, Canada.
FAU - Maze, Dawn
AU  - Maze D
AUID- ORCID: 0000-0002-4598-9380
AD  - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 
      Toronto, Canada.
FAU - Schuh, Andre C
AU  - Schuh AC
AD  - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 
      Toronto, Canada.
FAU - Yee, Karen Wl
AU  - Yee KW
AD  - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 
      Toronto, Canada.
FAU - Bankar, Aniket
AU  - Bankar A
AD  - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 
      Toronto, Canada.
FAU - Davidson, Marta B
AU  - Davidson MB
AD  - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 
      Toronto, Canada.
FAU - Richard-Carpentier, Guillaume
AU  - Richard-Carpentier G
AD  - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 
      Toronto, Canada.
FAU - Chan, Steven M
AU  - Chan SM
AD  - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 
      Toronto, Canada.
FAU - Sibai, Jad
AU  - Sibai J
AD  - University Health Network, Toronto, Canada.
FAU - Schimmer, Aaron D
AU  - Schimmer AD
AUID- ORCID: 0000-0003-4023-3899
AD  - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 
      Toronto, Canada.
FAU - Minden, Mark D
AU  - Minden MD
AD  - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 
      Toronto, Canada.
FAU - Sibai, Hassan
AU  - Sibai H
AUID- ORCID: 0000-0001-9030-8583
AD  - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 
      Toronto, Canada.
LA  - eng
PT  - Journal Article
DEP - 20240325
PL  - England
TA  - Hematology
JT  - Hematology (Amsterdam, Netherlands)
JID - 9708388
RN  - EC 3.5.1.1 (Asparaginase)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
SB  - IM
MH  - Humans
MH  - Aged
MH  - *Asparaginase/adverse effects
MH  - Retrospective Studies
MH  - *Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Polyethylene Glycols/adverse effects
OTO - NOTNLM
OT  - Acute lymphoblastic leukemia; ALL
OT  - chemotherapy
OT  - elderly patients
EDAT- 2024/03/25 12:43
MHDA- 2024/03/26 06:44
CRDT- 2024/03/25 10:03
PHST- 2024/03/26 06:44 [medline]
PHST- 2024/03/25 12:43 [pubmed]
PHST- 2024/03/25 10:03 [entrez]
AID - 10.1080/16078454.2024.2329027 [doi]
PST - ppublish
SO  - Hematology. 2024 Dec;29(1):2329027. doi: 10.1080/16078454.2024.2329027. Epub 2024 
      Mar 25.